The increasing research and development activities for the development of novel therapeutics for the treatment of T-cell lymphoma is expected to drive the market growth over the forecast period.
Market players are focused on thorough research in the field of T-cell lymphoma in order to develop newer and improved therapies for the treatment of T-cell lymphoma. Manufacturers in the global T-cell lymphoma market are engaged in obtaining regulatory approvals for their T-cell lymphoma treatment therapies.
For instance, in May 2020, Takeda Pharmaceutical Company Limited, a Japan based pharmaceutical company, received approval from China’s National Medical Products Administration (NMPA) for its injection ADCETRIS (brentuximab vedotin) indicated for treatment of patients with relapsed or refractory systemic Anaplastic Large Cell Lymphoma (a type of T-cell lymphoma).
Global T-cell Lymphoma Market Restraint
The side effects of chemotherapy drugs used in the treatment of T-cell lymphoma are the factors that are expected to hinder growth of the global T-cell lymphoma market over the forecast period. For instance, according to data provided by the American Cancer Society as of May 2020, chemotherapy drugs are generally associated with side effects such as fatigue, hair loss, anemia (low red blood cell counts), nausea and vomiting, appetite changes, constipation, diarrhea, and others.
T-cell Lymphoma Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients